OncoCyte Corp (OCX) — Cash Flow-to-Debt Ratio
OncoCyte Corp (OCX) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2025, meaning its operating cash flow of $-5.86 Million could theoretically repay 0% of its total liabilities ($50.14 Million) in one year. Explore OncoCyte Corp long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
OncoCyte Corp Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for OncoCyte Corp across 12 annual periods. Also explore OCX asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for OncoCyte Corp (2013–2024)
Year-by-year debt coverage analysis for OncoCyte Corp. For market capitalisation and broader financial context, see market value of OncoCyte Corp.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.44x | $-20.71 Million | $47.35 Million | ▲ +7.6% |
| 2023 | -0.47x | $-23.32 Million | $49.30 Million | ▲ +31.7% |
| 2022 | -0.69x | $-45.57 Million | $65.80 Million | ▼ -81.8% |
| 2021 | -0.38x | $-35.94 Million | $94.35 Million | ▲ +67.8% |
| 2020 | -1.18x | $-25.98 Million | $21.94 Million | ▲ +45.8% |
| 2019 | -2.19x | $-19.71 Million | $9.02 Million | ▼ -14.3% |
| 2018 | -1.91x | $-11.65 Million | $6.09 Million | ▲ +17.0% |
| 2017 | -2.30x | $-13.38 Million | $5.81 Million | ▼ -40.4% |
| 2016 | -1.64x | $-7.52 Million | $4.58 Million | ▲ +10.2% |
| 2015 | -1.83x | $-4.23 Million | $2.31 Million | ▼ -1066.6% |
| 2014 | -0.16x | $-1.16 Million | $7.43 Million | ▼ -3.1% |
| 2013 | -0.15x | $-710.00K | $4.67 Million | — |